Advanced Filters
noise

Lexington, Massachusetts Clinical Trials

A listing of Lexington, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,053 clinical trials
A Amanda Davis, LPN

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question[s] it aims to answer are: Is FX-909 safe and tolerable What is the right dose level for patients Participants will be asked to take FX-909 …

18 years of age All Phase 1
A Andrew H Nguyen, MA

Aging Well Through Interactions and Scientific Education - Action Plan (AgeWISE-AP)

The purpose of this study is to learn about the effects of AgeWISE-Action Plan (AgeWISE-AP), a 20-week program designed to provide education and individualized planning with a goal of improving brain health.

60 years of age All Phase N/A
A Andrew Branagan, MD, PhD

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the effectiveness of CB-011 in treating multiple myeloma that …

18 years of age All Phase 1
K Katrina Pedersen, M.D., M.S.

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

The purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor. The Phase II portion of the trial has not started recruiting.

18 years of age All Phase 1/2
I IreLee Ferguson, BA

Role of Parent Interpretation Bias in the Transmission of Anxiety to Children

Approximately 30% of children will experience an anxiety disorder, making anxiety the most common mental health problem among children in the United States. However, few children receive treatment and even our most effective anxiety treatments leave up to half of children in need of additional intervention. Despite the well-established role …

7 years of age All Phase N/A
V Valeriya Tsygankova

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.

40 years of age All Phase N/A
V Victoria Faustin, B.A.

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy

The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified …

50 years of age Male Phase N/A
J Janice Wolfe

The GORE® VIAFORT Vascular Stent Iliofemoral Study

This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction.

18 years of age All Phase N/A
A Ajay K. Gopal

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

18 years of age All Phase 1
N Nadine J. McCleary, MD, MPH

Resilience and Equity in Aging, Cancer, and Health (REACH)

The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

70 years of age All Phase N/A

Simplify language using AI